

1 **MOUSE ORGANOID CULTURE IS A SUITABLE MODEL TO STUDY**
2 **ESOPHAGEAL ION TRANSPORT MECHANISMS**

3
4 *Marietta Margaréta Korsós,¹ Tamás Bellák,^{2,3} Eszter Becskeházi,¹ Eleonóra Gál,¹ Zoltán*
5 *Veréb,⁴ Péter Hegyi,^{5,6,7} Viktória Venglovecz¹*

6
7 ¹Department of Pharmacology and Pharmacotherapy, University of Szeged, Szeged, Hungary

8 ²Department of Anatomy, Histology and Embryology, University of Szeged, Szeged,
9 Hungary

10 ³BioTalentum Ltd., Gödöllő, Hungary

11 ⁴Regenerative Medicine and Cellular Pharmacology Research Laboratory, Department of
12 Dermatology and Allergology, University of Szeged, Szeged, Hungary

13 ⁵First Department of Medicine, University of Szeged, Szeged, Hungary

14 ⁶Institute for Translational Medicine, Medical School, Szentágotthai Research Centre,
15 University of Pécs, Pécs, Hungary

16 ⁷Division of Gastroenterology, First Department of Medicine, Medical School, University of
17 Pécs, Pécs, Hungary

18
19 Running title: Ion transporters of esophageal organoids

20
21 Corresponding author:

22
23 *Viktória Venglovecz, Ph.D.*

24 Department of Pharmacology and Pharmacotherapy

25 University of Szeged

26 Szeged

27 HUNGARY

28 Telephone: +36 62 545 677

29 Fax: +36 62 545 680

30 Email: venglovecz.viktoria@med.u-szeged.hu

32 **ABSTRACT**

33 Altered esophageal ion transport mechanisms play a key role in inflammatory and cancerous
34 diseases of the esophagus, but epithelial ion processes have been less studied in the esophagus
35 because of the lack of a suitable experimental model. In this study, we generated 3D
36 esophageal organoids (EOs) from two different mouse strains and characterized the ion
37 transport processes of the EOs. EOs form a cell-filled structure with a diameter of 250–300
38 μm and generated from epithelial stem cells as shown by FACS analysis. Using conventional
39 PCR and immunostaining, the presence of Slc26a6 $\text{Cl}^-/\text{HCO}_3^-$ anion exchanger (AE), Na^+/H^+
40 exchanger (NHE), $\text{Na}^+/\text{HCO}_3^-$ cotransporter (NBC), cystic fibrosis transmembrane
41 conductance regulator (CFTR) and anoctamin 1 Cl^- channels were detected in EOs.
42 Microfluorimetric techniques revealed high NHE, AE, and NBC activities, whereas that of
43 CFTR was relatively low. In addition, inhibition of CFTR led to functional interactions
44 between the major acid–base transporters and CFTR. We conclude that EOs provide a
45 relevant and suitable model system for studying the ion transport mechanisms of esophageal
46 epithelial cells, and they can be also used as preclinical tools to assess the effectiveness of
47 novel therapeutic compounds in esophageal diseases associated with altered ion transport
48 processes.

49 Keywords: esophagus, ion transport, CFTR

50

51

52

53

54

55

56

58 **INTRODUCTION**

59 Research in recent years has increasingly highlighted the importance of ion transport
60 processes in inflammatory and cancerous diseases of the esophagus, as indicated by numerous
61 clinical studies (1, 2). These studies revealed altered expression of individual acid–base
62 transporters in Barrett’s esophagus, squamous cell carcinoma, and adenocarcinoma.
63 Conversely, the activity of these ion transporters has been less studied mainly because of the
64 lack of a suitable experimental model. Currently, a number of esophageal cell lines ranging
65 from normal cells to esophageal adenocarcinoma are available. Although cell lines are easy to
66 maintain, they have also limitations. Some cell lines are genetically modified to preserve their
67 proliferation or derived from pre-existing cancerous tissue, making them unsuitable for
68 studying physiological processes. In addition, because of their genetic instability, cells can
69 spontaneously differentiate into other cell types. The Ussing chamber is an old but commonly
70 used apparatus for studying esophageal permeability, and it is also suitable for investigating
71 transepithelial ion transport processes. However, application of this technique is often limited
72 by the condition, permeability, and short life span of the tissue, as well as reproducibility.
73 Organoids are three dimensional cell culture systems derived from progenitor or stem cells
74 that provide a near physiological *in vitro* model for studying epithelial function. The
75 discovery of organoids has greatly contributed to improved understanding of the ion transport
76 processes of individual organs such as the pancreas, colon, and airways (3-5). Esophageal
77 organoids (EOs) were first derived from mouse esophageal tissue by DeWard et al. (6). The
78 basal layer of the esophageal mucosa consists of a subpopulation of undifferentiated stem
79 cells with self-renewal ability and high proliferative capacity. After proliferation, cells
80 migrate toward the lumen while undergoing differentiation and replace the suprabasal cells
81 (7). Under appropriate culture conditions, organoids grown from stem cells develop a similar

82 structure as the organ of origin including the presence of several cell layers, but the difference
83 is that the outermost layer is composed of basal undifferentiated cells and the internal cell
84 mass is formed by differentiated keratinocytes (6).

85 Although EOs provide a suitable model for performing functional assays, the presence and
86 activity of ion transporters have not been investigated using EOs. In this study, we
87 characterized the activity and presence of ion transporters in mouse EOs for the first time. We
88 illustrated that mouse EOs express functionally active Na^+/H^+ exchanger (NHE), $\text{Na}^+/\text{HCO}_3^-$
89 cotransporter (NBC), $\text{Cl}^-/\text{HCO}_3^-$ anion exchanger (AE), and cystic fibrosis transmembrane
90 conductance regulator (CFTR) Cl^- channels. Our results provide insights into the ion transport
91 defects related to certain esophageal diseases and highlight a relevant experimental model
92 system for assessing the effects of drug molecules on esophageal ion transporters.

93

94

95

96

97

98

99

100

101

102

103

104

105

106

108 **MATERIALS AND METHODS**

109 **Mice**

110 Mice on the C57BL/6 and CD-1 backgrounds were bred and housed in standard plastic cages
111 under a 12-h:12-h light-dark cycle at room temperature ($23 \pm 1^\circ\text{C}$), and they were given free
112 access to standard laboratory chow and drinking solutions. Animal experiments were
113 conducted in accordance with the Guide for the Care and Use of Laboratory Animals (US
114 Department of Health and Human Services) and approved by the local Ethical Board of the
115 University of Szeged.

116 **Solutions and chemicals**

117 General laboratory chemicals were obtained from Sigma-Aldrich (Budapest, Hungary). 2,7-
118 Bis-(2-carboxyethyl)-5(6)-carboxyfluorescein acetoxymethyl ester (BCECF-AM) and N-
119 (ethoxycarbonylmethyl)-6-methoxyquinolinium bromide (MQAE) were purchased from
120 Molecular Probes Inc. (Eugene, OR, USA). BCECF-AM ($2 \mu\text{mol/L}$) and MQAE ($5 \mu\text{M}$) were
121 prepared in dimethyl sulfoxide (DMSO) and stored at -20°C . 4-Isopropyl-3-
122 methylsulfonylbenzoyl-guanidin methanesulfonate (HOE-642) was provided by Sanofi
123 Aventis (Frankfurt, Germany) and dissolved in DMSO. Nigericin (10 mM) was prepared in
124 ethanol and stored at -20°C . Forskolin was obtained from Tocris (Bristol, UK) and stored as a
125 250-mM stock solution in DMSO. The compositions of the solutions are presented in Table 1.
126 Standard HEPES-buffered solutions were gassed with 100% O_2 , and their pH was adjusted to
127 7.4 with NaOH. Standard $\text{HCO}_3^-/\text{CO}_2$ -buffered solutions were gassed with 95% $\text{O}_2/5\% \text{CO}_2$
128 to adjust their pH to 7.4. All experiments were performed at 37°C .

129 **Isolation of esophageal epithelial cells (EECs)**

130 After removal and longitudinal opening of the esophagus, the tissue was placed into dispase
131 solution (2 U/mL) and incubated at 37°C for 40 min. Then, the mucosa was peeled from the
132 submucosa using forceps, and the mucosa was incubated at 37°C in $1\times$ trypsin–EDTA

133 solution for 15 min, during which time the tissue was vortexed in every 2 min. To inactivate
134 trypsin, the trypsin–EDTA solution (with floating cells) was pipetted into soybean trypsin
135 inhibitor (STI) solution. The STI solution with the undigested tissue pieces was filter through
136 a 40- μ m cell strainer. Cells were then centrifuged for 10 min at 2000 rpm, and the cell pellet
137 was resuspended in 300 μ l of complete organoid culture medium.

138 **Generation of EOs**

139 The required volume of the cell suspension (7500 cells/well on a 24-well tissue culture plate)
140 was mixed with Matrigel[®] extracellular matrix at a 40:60 ratio and portioned in the wells,
141 followed by incubation at 37°C for 15 min to allow solidification of the gel. Complete
142 organoid culture medium was added to cover the Matrigel[®] and incubated at 37°C. After 3–4
143 days, organoid formation was visible. They reach their maximum size on day 8–12. The
144 growth medium consisted of Advanced Dulbecco's modified Eagle's medium/F12, 1 \times N2 and
145 1 \times B27 Supplements, 1 \times Glutamax (Gibco), 10 mM HEPES (Biosera), 2%
146 penicillin/streptomycin (Gibco), 1 mM N-acetyl-L-cysteine (Sigma), 100 ng/mL R-spondin 1,
147 100 ng/mL Noggin (both from Peprotech), 50 ng/mL mouse epidermal growth factor (R&D),
148 10 μ M Y27632 ROCK-kinase inhibitor (ChemCruz), and 5 % WNT3A conditioned medium.
149 Wnt3A conditioned medium was prepared by collecting the supernatant from L-Wnt3A cells
150 (ATCC CRL-2647) according to the manufacturer's protocol.

151 **Flow cytometry**

152 The expression of leucine-rich repeat-containing G-protein coupled receptor 5 (LGR5) and
153 cytokeratin 14 (CK14) was measured by flow cytometry on a FACSCalibur flow cytometer
154 (BD Biosciences Immunocytometry Systems, Franklin Lakes, NJ, USA) after staining the
155 cells on ice for 30 min with LGR5-PE (Origene, TA400001) and CK14-FITC (Novusbio,
156 NBP2-47720F) fluorochrome-conjugated antibodies and their matching isotype controls (PE
157 Mouse IgG1, κ Isotype Ctrl Antibody #400111 and FITC Mouse IgG3, κ Isotype Ctrl

158 Antibody #401317, both from Biolegend). The data were analyzed using Flowing Software
159 (Cell Imaging Core, Turku Center for Biotechnology, Finland), and the percentage of positive
160 cells was expressed as the mean \pm SD.

161 **Immunofluorescence staining and histology**

162 Organoid cultures were fixed with 4% PFA in 0.1 mol/L phosphate buffer for 1 h at room
163 temperature and washed three times with PBS. The fixed samples were cryoprotected in 30%
164 sucrose solution (in PBS) containing 0.01% sodium azide at 4°C until embedding in Tissue-
165 Tek O.C.T. compound (Sakura). The 16- μ m parallel sections were sectioned using a cryostat
166 (Leica CM 1850, Leica), mounted to gelatin-coated slides, and stored at -20°C until use.
167 After air-drying for 10 min, the sections were permeabilized with 0.1% Triton X-100 in PBS
168 and blocked for 1 h at 24°C with 3% BSA in PBS. The sections were then incubated with
169 primary antibodies (overnight, 4°C). On the next day, sections were washed in PBS three
170 times, and isotype-specific secondary antibodies were diluted in blocking buffer and applied
171 for 1 h at room temperature. The sections were washed three times with PBS and covered
172 using Vectashield[®] mounting medium containing DAPI (1.5 μ g/mL, Vector Laboratories),
173 which labeled the nuclei of the cells. Immunoreactive sections were analyzed using a BX-41
174 epifluorescence microscope (Olympus) equipped with a DP-74 digital camera and CellSens
175 software (V1.18, Olympus) or using an Olympus Fv-10i-W compact confocal microscope
176 system (Olympus) with Fluoview Fv10i software (V2.1, Olympus). For hematoxylin and
177 eosin (HE) staining, sections were incubated with Mayer's Hematoxylin solution (Sigma) for
178 5 min. Sections were washed with tap water and incubated into distilled water twice for 3 min
179 each. Sections were then incubated in 1% eosin solution in distilled water (Sigma) for 2 min.
180 Stained sections were dehydrating through 96 and 100% alcohol, cleared in xylene, and
181 mounted in DPX (Sigma). Microphotographs were taken using a DP-74 digital camera using a
182 light microscope (BX-41) and CellSens software (V1.18). All images were further processed

183 using the GNU Image Manipulation Program (GIMP 2.10.0) and NIH ImageJ analysis
184 software (imagej.nih.gov/ij). Details of the primary and secondary antibodies are presented in
185 Table 2.

186 **Gene expression analysis using RT-PCR**

187 Total RNA was isolated from the organoids using a NucleoSpin RNA Kit (Macherey–Nagel,
188 Düren, Germany). Two micrograms of RNA were reverse-transcribed using a High-Capacity
189 cDNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA, USA). PCR was
190 performed using DreamTaq DNA polymerase in a final volume of 20 μ L. All reactions were
191 performed under the following conditions: 94°C for 5 min; 30 cycles of 94°C for 30 s, 60°C
192 for 30 s, and 72°C for 1 min; and final elongation at 72°C for 10 min. The PCR products (10
193 μ L) were separated by electrophoresis on a 2% agarose gel and visualized using an
194 AlphaImager EC Gel Documentation System. As a positive control, kidney cDNA was used
195 in the case of Slc9a1, Slc9a2, Slc26a6, Slc4a4, and CFTR, and pancreas cDNA was used in
196 the case of Slc26a3 and anoctamine-1 (ANO-1). Primer sequences are presented in Table 3.

197 **Measurement of the intracellular Cl^- concentration ($[\text{Cl}^-]_i$) and pH microfluorimetry**

198 EOs were attached to a poly-L-lysine-coated cover slip (24 mm) forming the base of a
199 perfusion chamber and mounted on the stage of an inverted fluorescence microscope linked to
200 the Xcellence imaging system (Olympus). Organoids were then bathed with different
201 solutions at 37°C at a perfusion rate of 5–6 mL/min. Then, 6–12 region of interests (ROIs)
202 were examined in each experiments, and one measurement was obtained per second. $[\text{Cl}^-]_i$
203 was estimated using the fluorescent dye MQAE. Specifically, organoids were incubated with
204 MQAE (5 μ M) for 2–3 h at 37°C, and changes in $[\text{Cl}^-]_i$ were determined by exciting the cells
205 at 340 nm with emitted light monitored at 380 nm. Fluorescence signals were normalized to
206 the initial fluorescence intensity (F/F_0) and expressed as relative fluorescence. To determine
207 intracellular pH (pH_i), cells were loaded with the pH-sensitive fluorescent dye BCECF-AM (2

208 μM , 30 min, 37°C) and excited at 490 and 440 nm. The 490/440 fluorescence emission ratio
209 was measured at 535 nm. The calibration of the fluorescence emission ratio to pH_i was
210 performed using the high- K^+ /nigericin technique, as previously described (8, 9).

211 **Measurement of the activity of the acid–base transporters**

212 To estimate the activity of NHE and NBC, the NH_4Cl prepulse technique was used. Briefly,
213 exposure of EOs to 20 mM NH_4Cl for 3 min induced an immediate rise in pH_i because of the
214 rapid entry of lipophilic basic NH_3 into the cells. After the removal of NH_4Cl , pH_i rapidly
215 decreased. This acidification is caused by the dissociation of intracellular NH_4^+ to H^+ and
216 NH_3 , followed by the diffusion of NH_3 from the cells. In standard HEPES-buffered solution,
217 the initial rate of pH_i ($\Delta\text{pH}/\Delta t$) recovery from the acid load (over the first 60 s) reflects the
218 activities of NHEs, whereas in $\text{HCO}_3^-/\text{CO}_2$ -buffered solutions, the rate represents the
219 activities of both NHE and NBC (10).

220 Two independent methods were used to estimate AE activity. Using the NH_4Cl
221 prepulse technique, the initial rate of pH_i recovery from alkalosis in $\text{HCO}_3^-/\text{CO}_2$ -buffered
222 solutions was analyzed (10). Previous data indicated that under these conditions, the recovery
223 over the first 30 s reflects the activity of AE (10). The Cl^- withdrawal technique was also
224 applied, in which removal of Cl^- from the external solution causes immediate and reversible
225 alkalization of the pH_i because of the reverse operation of AE under these conditions.
226 Previous data illustrated that the initial rate of alkalization over the first 60 s reflects the
227 activity of AE (11).

228 **Statistical analysis**

229 Results are expressed as the mean \pm SD. Statistical analyses were performed using analysis of
230 variance. $p \leq 0.05$ was accepted as significant.

231

232 RESULTS

233 Characterization of EO cultures

234 Isolated EECs were plated in Matrigel supplemented with organoid culture medium at a final
235 concentration of 40%. On the 3rd day after plating, organoid formation was observed, and
236 therefore, we assessed organoid growth starting from day 3 (Fig. 1A). The size of the
237 organoids increased steadily in the following days, peaking between days 7 and 9. Organoids
238 between 50 and 150 μm in size were used for our experiments. HE staining of the organoids
239 illustrated that cells are located in several layers inside the organoids, matching the structure
240 of normal esophageal tissue (Fig. 1B). The inner cell mass consisted of differentiated cells
241 that move from the periphery to the inside of the organoids during their maturation. In
242 addition, the centers of some organoids were empty, or they contained keratinized materials
243 produced by the cells. To verify that organoids are generated from stem cells, we used the
244 stem cell marker LGR5. Immunofluorescence staining revealed strong LGR5 expression in
245 both C57BL/6 and CD-1 organoids (Fig. 1C), and FACS analysis demonstrated that $42.70 \pm$
246 7.27% of the isolated C57BL/6 EECs and $46.46 \pm 7.81\%$ of the isolated CD-1 EECs were
247 LGR5-positive (Fig. 2A and B). In the next step, we verified that the organoids were derived
248 from single EECs. CK14 is a cytoplasmic keratin expressed in the basal SECs (12, 13). As
249 presented on Fig. 1C, the outer cell layer of the organoids was CK14-positive, indicating that
250 the organoids originate from the mucosa and display a morphologically similar structure as
251 normal esophageal tissue. FACS analysis indicated that $45.29 \pm 9.25\%$ of the isolated
252 C57BL/6 EECs and $55.32 \pm 7.80\%$ of the isolated CD-1 EECs were CK14-positive (Fig. 2A
253 and B). Interestingly, there was a slight difference in the double-positive (LGR5 and CK14)
254 fraction. The proportion of double-positive cells was higher in CD-1 mouse organoids (35.37
255 $\pm 1.24\%$) than in C57BL/6 mouse organoids ($19.34 \pm 2.03\%$, Fig. 2C).

256

257 mRNA and protein expression of ion transporters in EOs

258 The mRNA expression of ion transporters was investigated using conventional RT-PCR. We
259 revealed the presence of *Slc9A1* (NHE-1), *Slc9A2* (NHE-2), *Slc26a6* (PAT1), *CFTR*, *Scl4a4*
260 (NBCe1B), and *ANO1* in both the C57BL/6 and CD-1 organoids (Fig. 3A). The presence of
261 these transporters was also confirmed at the protein level using immunohistochemistry (Fig.
262 3B and C). By contrast, the *Slc26a3* (DRA) transporter could not be detected at either the
263 mRNA or protein level. Because the CFTR Cl⁻ channel and Slc26a6 interact with each other
264 in several secretory epithelia (14), we examined the colocalization of these two transporters
265 on the organoids. CFTR and Slc26a6 exhibited diffuse staining throughout cells without
266 special localization to the apical or basal membrane. Interestingly, Slc26a6 staining was more
267 detectable in cells on the periphery, whereas in the case of CFTR, central cells also displayed
268 positive staining.

269 Resting pH_i of EOs and determination of buffering capacity

270 To investigate the pH regulatory mechanisms of EO cultures, we initially determined the
271 resting pH_i of the cells. EOs were exposed to standard HEPES solution (pH 7.4), followed by
272 a 5-min exposure to a high-K⁺/nigericin-HEPES solution at pH 7.2, 7.4, and 7.6 (Fig. 4A).
273 The resting pH_i of the organoids was determined using the classical linear model (8, 9). The
274 resting pH_i of C57BL/6 organoids was 7.61 ± 0.03, whereas that of CD-1 organoids was 7.58
275 ± 0.03. The total buffering capacity (β_{total}) of EOs was estimated using the NH₄⁺ prepulse
276 technique, as previously described (Fig. 4B) (10, 15). Briefly, organoids were exposed to
277 various concentrations of NH₄Cl in nominally Na⁺- and HCO₃⁻-free solutions, and β_{total} of the
278 cells was calculated using the following equation: β_{total} = β_i + β_{HCO₃⁻} = β_i + 2.3 × [HCO₃⁻]_i,
279 where β_i describes the ability of intrinsic cellular components to respond to buffer changes of
280 pH_i (calculated by the Henderson-Hasselbach equation) and β_{HCO₃⁻} is the buffering capacity
281 of the HCO₃⁻/CO₂ system. The measured rates of pH_i change (ΔpH/Δt) were converted to

282 transmembrane base flux $J(B^-)$ using the following equation: $J(B^-) = \Delta pH / \Delta t \times \beta_{total}$. β_{total} at
283 the initial pH_i was used to calculate $J(B^-)$. We denoted base influx as $J(B)$ and base efflux
284 (secretion) as $-J(B^-)$.

285 **Activity of NHE**

286 NHE is an integral plasma membrane protein that mediates the electroneutral exchange of
287 extracellular Na^+ and intracellular H^+ , thereby playing an important role in the alkalization of
288 cells. NHE activity was investigated by removing extracellular Na^+ from the external solution.
289 As presented in Figure 5A, Na^+ removal induced a sharp decrease in pH_i , suggesting that EOs
290 express functionally active NHE. There was no significant difference in the rate ($-J(B^-)$) and
291 extent (ΔpH_{max}) of the pH_i decrease between the two mouse strains (Fig. 5B and C). The
292 presence of NHE was also confirmed using the ammonium prepulse technique (Fig. 5D).
293 Organoids were exposed to 20 mM NH_4Cl (3 min) in standard HEPES-buffered solution,
294 which induced a high degree of intracellular alkalization because of the rapid influx of NH_3
295 into cells. After removing NH_4Cl from the bath, pH_i dramatically decreased and then returned
296 to baseline. Under these conditions, recovery from acidosis reflects the activity of NHE. In the
297 absence of Na^+ , recovery from acidosis was negligible, indicating that in the absence of
298 HCO_3^- , NHE is mainly responsible for the alkalization of cells (Fig. 5D and E). The NHE
299 gene family contains several isoforms (NHE-1–9) with different functions and expression
300 patterns (16). To identify the most active isoform on organoids, the NHE isoform specific
301 inhibitor HOE-642 was used. This inhibitor blocks NHE-1 and NHE-2 isoforms in a
302 concentration-dependent manner. At a concentration of 1 μM , only the NHE-1 isoform is
303 inhibited, whereas 50 μM HOE-642 inhibits both isoforms (2, 17). We chose this inhibitor
304 because our previous studies on human esophageal cell lines indicated that these two isoforms
305 are responsible for the majority of NHE activity (2). Organoids were acid-loaded with 20 mM
306 NH_4Cl followed by a 3-min incubation in Na^+ -free HEPES solution. In the absence of Na^+ ,

307 the NHE is blocked, and thus, pH_i is not regenerated. Upon the re-administration of
308 extracellular Na^+ , NHE regained its function, and its activity could be estimated from the
309 initial rate of pH_i recovery over the first 60 s. As presented in Fig. 6A, 1 μM HOE-642
310 decreased pH_i recovery by $87.81 \pm 1.17\%$ in C57BL/6 organoids and $82.37 \pm 7.32\%$ in CD-1
311 organoids, whereas the administration of 50 μM HOE-642 resulted in further decreases (97.54
312 $\pm 0.52\%$ in C57BL/6 organoids and $92.91 \pm 3.76\%$ in CD-1 organoids, Fig. 6B). These data
313 indicate that although NHE-1 has higher activity, NHE-2 is also active on organoids. The fact
314 that some activity remained even in the presence of 50 μM HOE-642 suggests the presence of
315 other Na^+ -dependent acid-extruding mechanisms.

316 **Activity of NBC**

317 NBC is an electrogenic transporter that mainly localizes to the basolateral membrane in most
318 epithelia, in which it mediates the cotransport of Na^+ and HCO_3^- into cells. Inside cells,
319 HCO_3^- binds H^+ and causes intracellular alkalization. Therefore, in standard $\text{HCO}_3^-/\text{CO}_2$ -
320 buffered external solution, both NHE and NBC fight against cellular acidosis. NBC activity
321 was investigated by the NH_4Cl prepulse technique (Fig. 7A). Administration of $\text{HCO}_3^-/\text{CO}_2$
322 rapidly and greatly decreased pH_i because of the quick diffusion of CO_2 into the cytoplasm.
323 Significant pH_i recovery was observed after acidification, suggesting the important role of
324 HCO_3^- efflux into EOs through NBC (Fig. 7A). After the NH_4Cl pulse, recovery from
325 alkalosis was more rapid than observed in the presence of standard HEPES-buffered solution,
326 indicating that in addition to NHE, NBC is also active in the presence of HCO_3^- . Removal of
327 Na^+ from the external solution almost completely abolished the recovery from acidosis. To
328 determine NBC activity, NHE function was blocked by the non-specific NHE inhibitor
329 amiloride, which was added 1 min before and during the re-administration of Na^+ . As
330 presented in Fig. 7A and B, the recovery from acidosis was decreased by $61.88 \pm 5.3\%$ in
331 C57BL/6 organoids and $62.18 \pm 7.3\%$ in CD-1 organoids in the presence of amiloride,

332 indicating that NHE is responsible for much of the recovery from acidosis, but there is also
333 functionally active NBC on the cells. Interestingly, we found a significant difference in
334 recovery following Na^+ deprivation between the C57BL/6 and CD-1 organoids, suggesting
335 greater NBC activity in C57BL/6 mice.

336 **Activity of the $\text{Cl}^-/\text{HCO}_3^-$ exchanger**

337 The HCO_3^- transporter family includes several transport proteins, of which Slc26 proteins
338 functions as an electroneutral $\text{Cl}^-/\text{HCO}_3^-$ exchanger. Among the Slc26 exchangers, the
339 presence of Slc26a6 (PAT1) was detected at both the mRNA and protein level in the C57BL/6
340 and CD-1 organoids. Slc26a6 mediates Cl^- and HCO_3^- exchange with a $1\text{Cl}^-/2\text{HCO}_3^-$
341 stoichiometry. To determine whether this $\text{Cl}^-/\text{HCO}_3^-$ exchanger is functionally active on the
342 organoids, the Cl^- removal technique was used (Fig. 8A–C). In the presence of external Cl^- ,
343 Slc26a6 mediates the efflux of HCO_3^- and the uptake of Cl^- , therefore playing role in the
344 acidification of cells. Removal of Cl^- from standard $\text{HCO}_3^-/\text{CO}_2$ -buffered solution induced
345 strong alkalization because of the reverse mode of the exchanger (Fig. 8A). By contrast, in the
346 absence of HCO_3^- , Cl^- removal caused minimal, reversible alkalization (Fig. 8B). The
347 presence of functionally active AE has been also confirmed by the NH_4Cl prepulse technique
348 (Fig. 8D and E). We previously illustrated that in the presence of HCO_3^- , the initial rate of
349 recovery (30 s) from alkalosis reflects the activity of $\text{Cl}^-/\text{HCO}_3^-$ exchangers (11, 18). As
350 presented in Fig. 8E, there was no significant difference in AE activity between the two
351 mouse organoids.

352 **Activity of CFTR**

353 The CFTR Cl^- channel, which is present on most epithelial cells, mediates the efflux of Cl^-
354 from cells. The presence of this ion channel has been detected at both the mRNA and protein
355 level in organoids; therefore, we also investigated its activity using the Cl^- sensitive
356 fluorescent dye MQAE and CFTR activator forskolin. As presented in Fig. 9A and B, the

357 administration of 10 μ M forskolin caused a small increase in initial rate of Cl^- efflux ($19.61 \pm$
358 4.52% in C57BL/6 organoids and $21.83 \pm 9.72\%$ in CD-1 organoids), and Cl^- loss reached
359 steady state after approximately 10 min. The effect of 5 μ M forskolin was negligible. To
360 investigate whether there is a functional relationship between CFTR and the acid–base
361 transporters, the activity of the transporters was examined in the presence of the CFTR
362 inhibitor CFTRinh-172 (10 μ M, Fig. 9C–E). Using the NH_4Cl prepulse technique, we found
363 that the activity of AE was significantly decreased by CFTR inhibition ($18.60 \pm 3.34\%$ in
364 C57BL/6 organoids and $35.71 \pm 11.77\%$ in CD-1 organoids, Fig. 9D), whereas recovery from
365 acidosis was only inhibited in C57BL/6 organoids (Fig. 9E).

366

367 **CONCLUSION**

368

369 The present study is the first to describe and functionally characterize the most common ion
370 transport processes on EOs using two frequently used laboratory mouse strains (C57BL/6 and
371 CD-1). Regulation of pH_i in epithelial cells is crucial, as most biological processes are
372 affected by changes in pH. Ion transporters are involved in the regulation of pH_i and
373 extracellular pH. Specifically, the transporters are polarized on epithelial cells, ensuring the
374 unidirectional movement of substances. Esophageal ion transport processes were most
375 intensively studied in the 1990s, mostly using primary tissue. These studies investigated the
376 basic acid–base transporters and characterized the effect of acid and bile on the function of
377 these transporters (1). Although extremely important information was obtained from these
378 investigations, most of the findings are obsolete, and the primary tissues used in these studies
379 did not permit the specific investigation of a given transporter. The development of organoid
380 cultures was a significant breakthrough in the examination of individual organs and tissues.
381 Their biggest advantages include their easy maintenance, suitability for longer studies, and

382 recapitulation of physiological conditions. In addition, organoids can be frozen and passaged,
383 allowing the function of different transporters to be compared even on the same genetic
384 background.

385 To investigate the ion transport mechanisms of EOs, we initially determined the resting pH
386 and total buffering capacity of the cells. We found that the starting pH of the organoids was
387 nearly 7.6 in CD-1 organoids and slightly higher than 7.6 in C57BL/6 organoids. This
388 unusually high initial pH has also been detected in human and rabbit esophageal cells (19,
389 20). The cause of the high resting pH_i is not fully known. Presumably, this finding can be
390 explained by the excessive activity of the alkalizing transporters that act against acidosis. Our
391 results demonstrated the presence of a Na^+ -dependent H^+ efflux mechanism on EOs, probably
392 NHE, which was functionally active. The presence of NHE-1 on rat and rabbit EECs was
393 previously demonstrated (21). By contrast, NHE-1 and NHE-2 expression is extremely low in
394 normal human esophagus but strong in Barrett's and esophageal cancer (2, 22, 23). HOE-642
395 largely inhibited NHE function, suggesting that more than 90% of functionally active NHEs
396 in EOs are NHE-1 and NHE-2. Concerning the residual activity, other NHE isoforms or a
397 proton pump is presumably responsible. One possible candidate is NHE3, which was
398 previously detected on human esophageal cells, in which it participate in the formation of
399 dilated intercellular spaces, and the expression of this isoform increases with the severity of
400 GERD (24, 25). Immunolocalization of NHE-1 and NHE-2 demonstrated that NHE-1
401 expression was mostly observed in the periphery, whereas NHE-2 staining was more
402 pronounced in the inner cell layers. The different localization of NHE-1 and NHE-2 can be
403 explained by the fact that organoids are composed of different types of cells. The outermost
404 cell layer of the organoids consists of basal cells, whereas the inner cell layers are composed
405 of differentiated keratinocytes. This indicates that NHE-1 is mainly expressed in basal cells,
406 whereas NHE-2 is expressed in keratinocytes. Our finding that NHE-1 is mainly located in

407 basal cells is consistent with the observation that NHE-1 expression is very extremely in
408 human SECs (2, 22, 23).

409 NBC is another transporter that can protect cells from acidosis. We revealed the presence of
410 NBC in EOs, and it plays an important role in pH_i regulation. CO_2 -induced acidosis was
411 almost completely reversed, which can be explained by the influx of HCO_3^- through NBC.
412 Furthermore, we found a significant difference in recovery from acidosis in the presence and
413 absence of HCO_3^- , and fairly significant recovery was observed in the presence of amiloride.
414 Taken together, these data strongly indicate that EOs express functionally active NBC. The
415 presence of NBC has to date been identified in submucosal glands, in which it plays role in
416 HCO_3^- secretion (26, 27). The presence of NBC has also been demonstrated in human EECs,
417 and similarly as NHE, its expression is increased in Barrett's carcinoma (2). The role of NBC
418 in SECs is not entirely clear, but presumably, it might play a central role in the regulation of
419 pH_i and transcellular transport of HCO_3^- . Because NBC mediates HCO_3^- uptake, its present
420 also presupposes the presence of AE on these cells. Using a microfluorimetric technique, we
421 detected a Cl^- -dependent HCO_3^- efflux mechanism on EOs. Removal of Cl^- from the external
422 solution in the presence of HCO_3^- induced strong alkalosis via the reverse mode of the
423 $\text{Cl}^-/\text{HCO}_3^-$ exchanger. In addition, the presence of HCO_3^- significantly increased the rate of
424 recovery from alkalosis. Previous studies by our laboratory demonstrated that recovery from
425 alkalosis in the presence of HCO_3^- is the result of HCO_3^- efflux through the $\text{Cl}^-/\text{HCO}_3^-$
426 exchanger (11, 18). Among the $\text{Cl}^-/\text{HCO}_3^-$ exchangers, the presence of Na^+ -dependent and
427 Na^+ -independent transporters was demonstrated on rabbit SECs (28). In addition, the presence
428 of Slc26a6 was detected on SMGs, thereby mediating HCO_3^- secretion together with NBC
429 and CFTR (26, 27). In EOs, strong Slc26a6 expression was found at both the mRNA and
430 protein level, whereas Slc26a3 expression was weak and non-specific. The Slc26a6
431 transporter is primarily located on the apical membrane of secretory epithelial cells, in which

432 it plays an essential role in HCO_3^- secretion (29). Because the esophageal epithelium is not a
433 typical secretory epithelium, the presence of this transporter on EOs is unusual. In addition,
434 Slc26a6 expression was more pronounced at the periphery, indicating that basal cells have
435 some HCO_3^- -secreting capacity. In many secretory epithelia, Slc26 AEs interact with the
436 CFTR Cl^- channel in the regulation of HCO_3^- secretion (30, 31). To investigate the presence
437 of CFTR and its coexpression with the Slc26a6 transporter, we investigated the colocalization
438 of these transporters using immunostaining. As an interesting finding of our study, the CFTR
439 Cl^- channel is expressed on EOs. Immunolocalization illustrated that both peripheral and
440 central cells highly express CFTR. Costaining of CFTR and Slc26a6 revealed some
441 colocalization, mainly in cells on the periphery, indicating that the two transporters interact
442 with each other. To investigate the functional interaction between CFTR and Slc26a6, the
443 microfluorimetric technique was used. The specific CFTR activator forskolin concentration-
444 dependently increased the activity of CFTR, although the response to forskolin was relatively
445 low even in the presence of supramaximal concentrations, indicating that CFTR channel
446 activity is lower than usually observed for secretory epithelia, such as those in the pancreas or
447 lungs (32). The presence of the CFTR inhibitor CFTRinh-172 decreased the rate of recovery
448 from alkalosis in both C57BL/6 and CD-1 organoids, indicating that the channel interacts
449 with the AE. Interestingly, we found that CFTR inhibition also significantly reduced recovery
450 from acidosis in C57BL/6 organoids. Because both NBC and NHE are involved in recovery
451 from acidosis in the presence of HCO_3^- , CFTR interacts with one of these transporters, but
452 this type of interaction was not previously described. CFTR has been detected in the ductal
453 cells of porcine submucosal glands, in which it localizes primarily to the apical membrane and
454 plays an important role in ductal HCO_3^- secretion (26). It has also been detected in SECs, in
455 which its presence is restricted to the basal cell layer (33). In SECs, CFTR mediates Cl^-
456 transport together with the voltage-gated Cl^- channel ClC-2, which plays a pivotal role in

457 protection against acid-induced injury, as demonstrated with the CIC-2 agonist lubiprostone
458 (33). Because lubiprostone has been illustrated to activate CFTR (34, 35), the role of CFTR in
459 this process has been postulated. The protective role of CFTR was also demonstrated in BE
460 and esophageal cancer (36-40). These experiments demonstrated that CFTR plays a protective
461 role against esophageal cancer, and overexpression of this channel is associated with good
462 prognosis in squamous cell carcinoma. We also revealed the presence of the Ca^{2+} -activated
463 Cl^- channel ANO1 or TMEM16A in EOs. One study examined the presence of ANO1 in the
464 esophageal epithelium and indicated that its expression is increased in eosinophilic
465 esophagitis and correlated with the severity of the disease. Furthermore, ANO1 has been
466 reported to play central roles in the proliferation of basal zone hyperplasia via an IL-13–
467 mediated pathway (41).

468 In this study, we uncovered for the first time the presence of the major epithelial ion
469 transporters in EOs. We demonstrated that NHE, NBC, AE, and the CFTR Cl^- channel are
470 active in EOs, and there was no significant difference in the expression and activity of NHE,
471 AE, and CFTR between the two mouse strains. We can conclude that the EOs comprise a
472 suitable experimental system to investigate ion transport processes, and therefore, they can be
473 used to study the role of ion transporters in different esophageal diseases or test drug
474 molecules that affect the function of ion transporters.

475

476 **FUNDING**

477

478 This study was supported by the National Research, Development and Innovation Office
479 (FK123982), the National Research, Development and Innovation Office, by the Ministry of
480 Human Capacities (EFOP 3.6.2-16-2017-00006).

481

482 **CONFLICTS OF INTEREST**

483

484 The authors hereby declare that there are no conflicts of interests to disclose.

485

486 **AUTHORS CONTRIBUTION STATEMENT**

487 MMK performed PCR and microfluorimetric measurements and analysed the data. TB did the
488 immunostainings. EB participated in the culturing and microfluorimetric measurements of
489 organoids. EG and ZV carried out FACS experiments and analysis. PH contributed to the
490 interpretation of the results. VV supervised the project and drafted the manuscript. All authors
491 discussed the results and contributed to the final manuscript. All authors approved the final
492 version of the manuscript, agreed to be accountable for all aspects of the work in ensuring that
493 questions related to the accuracy or integrity of any part of the work are appropriately
494 investigated and resolved; and all persons designated as authors qualify for authorship, and all
495 those who qualify for authorship are listed.

496

497

498

499

500

501 **FIGURE LEGENDS**

502

503 **Fig. 1 Characterization of esophageal organoids (EOs).** (A) Representative bright field
504 images of EOs grown for 9 days from freshly isolated esophageal mucosa. Images were taken
505 using an Olympus IX71 inverted microscope. The scale bar represents 100 μm . (B)
506 Hematoxylin and eosin staining of EOs developed from C57BL/6 and CD-1 mouse
507 esophageal tissue. The scale bar represents 100 μm (upper line) and 50 μm (bottom line),
508 respectively. (C) Confocal images of EOs stained for leucine-rich repeat-containing G-protein
509 coupled receptor 5 (LGR5, green), cytokeratin 14 (CK14, red), and DAPI (blue). The scale
510 bar represents 100 μm (main photo) and 50 μm (inset photo), respectively.

511 **Fig. 2 Flow cytometry analysis of leucine-rich repeat-containing G-protein coupled**
512 **receptor 5 (LGR5) and cytokeratin 14 (CK14) expression.** (A) Percentage of LGR5- and
513 CK14-positive cells in the cell suspension of esophageal mucosa obtained from CD-1 and
514 C57BL/6 mice. (B) Representative histograms of the FACS analysis with the respective
515 isotype controls (gray color). (C) Representative dot plots present CK14 and LGR5 double-
516 positive cells. $n = 3$

517 **Fig. 3 Expression of ion transporters in esophageal organoids (EOs).** (A) Mature EOs
518 were collected 9 days after plating, and RNA was prepared from the organoids. Gene
519 expression of ion transporters was investigated with traditional RT-PCR analysis. (B)
520 Immunostaining of EOs for Slc9a1 (first line), Slc9a2 (second line), Slc26a3 (third line),
521 Slc4a4 (fourth line), and ANO1 (fifth line). The scale bar represents 100 μm (main photo) and
522 50 μm (inset photo), respectively.

523 (C) Costaining of Slc26a6 (red) and CFTR (green). The scale bar represents 50 μm (upper
524 line), 25 μm (middle line) and 10 μm (bottom line), for both mice strains.

525 **Fig. 4 Initial pH and buffering capacity of esophageal organoids.** (A) Organoids were
526 exposed to nigericin/high-K⁺-HEPES solution at pH 7.2, 7.4, and 7.6. The resting
527 intracellular pH (pH_i) was calculated from this three-point calibration using the classic linear
528 model. (B) Organoids were exposed to various concentrations of NH₄Cl in nominally Na⁺-
529 and HCO₃⁻-free solutions, and the total buffering capacity (β_{total}) of the cells was calculated
530 using the following equation: β_{total} = β_i + β_{HCO₃⁻} = β_i + 2.3 × [HCO₃⁻]_i, where β_i refers to the
531 ability of intrinsic cellular components to buffer changes of pH_i and β_{HCO₃⁻} is the buffering
532 capacity of the HCO₃⁻/CO₂ system. The black line shows the organoid response isolated from
533 C57BL/6 mice, whereas the red line shows the organoid response isolated from CD-1 mice. n
534 = 17-19

535 **Fig. 5 Investigation of Na⁺/H⁺ exchanger (NHE) activity in esophageal organoids (EOs).**
536 (A) Removal of Na⁺ from standard HEPES solution caused rapid intracellular acidosis in
537 organoids isolated from C57BL/6 (black line) and CD-1 (red line) mice confirmed the
538 presence of a Na⁺-dependent H⁺ efflux mechanism. Summary data for the maximal
539 intracellular pH (pH_i) change (ΔpH_{max}) (B) and the calculated base flux (J(B⁻)) (C) induced
540 by Na⁺ removal. (D) Recovery from acid load reflects the activity of NHE in standard
541 HEPES-buffered solution. After the second NH₄Cl pulse, Na⁺ was removed from the external
542 solution to investigate the activity of NHE. (E) Summary bar chart presents the initial rate of
543 pH_i recovery (J(B⁻)) from an acid load. J(B⁻) was calculated from the dpH/dt obtained by
544 linear regression analysis of pH_i measurements made over the first 60 s after Na⁺ removal
545 (one pH_i measurement was made per second). The buffering capacity at the initial pH_i was
546 used for the calculation of J(B⁻) (see Methods). Data are presented as the mean ± SD. a: p ≤
547 0.05 vs. Control. n = 19-23

548 **Fig. 6 Investigation of Na⁺/H⁺ exchanger (NHE) isoforms on esophageal organoids**
549 **(EOs).** (A) Representative intracellular pH (pH_i) curves (black line, C57BL/6; red line, CD-1)

550 present the recovery from acidosis in the presence of 1 and 50 μM HOE-642. **(B)** Summary
551 data of the calculated activities of the different NHE isoforms in the presence of the isoform-
552 selective NHE inhibitor HOE-642. The rate of pH recovery ($J(\text{B}^-)$) was calculated from the
553 $\Delta\text{pH}/\Delta\text{t}$ obtained via linear regression analysis of the pH_i measurement performed over the
554 first 60 s of recovery from the lowest pH_i level (initial pH_i). The buffering capacity at the
555 initial pH_i was used to calculate $J(\text{B}^-)$. Data are presented as the mean \pm SD. a: $p \leq 0.05$ vs.
556 Control. b: $p \leq 0.05$ vs. 1 μM HOE-642. n = 5–11

557 **Fig. 7 Investigation of $\text{Na}^+/\text{HCO}_3^-$ cotransporter (NBC) activity in esophageal organoids**
558 **(EOs).** **(A)** Representative intracellular pH (pH_i) curves (black line, C57BL/6; red line, CD-1)
559 present the recovery from acidosis in the presence of 0.2 mM amiloride. **(B)** Summary data
560 present the calculated activity of NBC in the presence of the Na^+/H^+ exchanger (NHE)
561 inhibitor amiloride. The rate of acid recovery ($J(\text{B}^-)$) was calculated from the $\Delta\text{pH}/\Delta\text{t}$
562 obtained via linear regression analysis of the pH_i measurement performed over the first 60 s
563 of recovery from the lowest pH_i (initial pH_i). The buffering capacity at the initial pH_i was
564 used to calculate $J(\text{B}^-)$. Data are presented as the mean \pm SD. a: $p \leq 0.05$ vs. Control. b: $p \leq$
565 0.05 vs. C57BL/6. n = 15–17

566 **Fig. 8 Investigation of $\text{Cl}^-/\text{HCO}_3^-$ exchanger activity in esophageal organoids.**

567 $\text{Cl}^-/\text{HCO}_3^-$ exchanger activity was investigated by the Cl^- removal technique in the presence
568 **(A)** and absence **(B)** of $\text{HCO}_3^-/\text{CO}_2$ (black line, C57BL/6; red line, CD-1) **(C)** The rate of acid
569 recovery $J(\text{B}^-)$ was calculated from the dpH/dt obtained via linear regression analysis of
570 intracellular pH (pH_i) measurements performed over the first 60 s after exposure to the Cl^- -
571 free solution. The buffering capacity at the initial pH_i was used to calculate $J(\text{B}^-)$. n = 4-15
572 **(D)** The activity of the $\text{Cl}^-/\text{HCO}_3^-$ exchanger was also measured using the alkali loading
573 method and expressed as calculated $J(\text{B}^-)$, which was calculated from the dpH/dt obtained via
574 linear regression analysis of pH_i measurements performed over the first 30 s of recovery from

575 the highest pH_i level (initial pH_i) achieved in the presence of NH_4Cl . The buffering capacity
576 at the start point pH_i was used for the calculation of $J(\text{B}^-)$. Data are presented as the mean \pm
577 SD. $n = 25-37$

578 **Fig. 9 Investigation of cystic fibrosis transmembrane conductance regulator (CFTR)**
579 **activity in esophageal organoids (EOs).** (A) Representative intracellular pH (pH_i) curves
580 (black line, C57BL/6; red line, CD-1) present the effect of forskolin on Cl^- efflux. (B)
581 Summary data for the maximal fluorescence intensity changes. $n = 19-22$ (C) Representative
582 pH_i curves present the recovery from acid and alkali loading in the presence of $10 \mu\text{M}$
583 CFTRinh-172. The rates of alkali recovery ($-J(\text{B}^-)$) (D) and acid recovery ($J(\text{B}^-)$) (E) were
584 calculated from the $\Delta\text{pH}/\Delta t$ obtained via linear regression analysis of pH_i measurements
585 performed over the first 30 and 60 s of recovery from the highest and lowest pH_i (initial pH_i),
586 respectively. The buffering capacity at the initial pH_i was used to calculate $J(\text{B}^-)$ and $-J(\text{B}^-)$.
587 Data are presented as the mean \pm SD. a: $p \leq 0.05$ vs. Control. b: $p \leq 0.05$ vs. C57BL/6. $n = 3-$
588 6

589 **Table 1.** Compositions of the solutions. Values are presented in mM.

590 **Table 2.** List of primary and secondary antibodies used in the study

591 **Table 3.** Primer sequences used in the study

592

593

594

595

596

597

598

599

600

601

602

603

604 **REFERENCES**

605

- 606 1. **Becskehazi E, Korsos MM, Eross B, Hegyi P, and Venglovecz V.** OEsophageal Ion
607 Transport Mechanisms and Significance Under Pathological Conditions. *Front Physiol* 11:
608 855, 2020.
- 609 2. **Laczko D, Rosztoczy A, Birkas K, Katona M, Rakonczay Z, Jr., Tiszlavicz L,**
610 **Roka R, Wittmann T, Hegyi P, and Venglovecz V.** Role of ion transporters in the bile acid-
611 induced esophageal injury. *Am J Physiol Gastrointest Liver Physiol* 311: G16-31, 2016.
- 612 3. **de Jonge H.R. BMJC, Strubberg A.M., Liu J., Clarke L.L.** Organoids as a Model
613 for Intestinal Ion Transport Physiology. In: *Ion Transport Across Epithelial Tissues and*
614 *Disease*, edited by Hamilton K.L. DDCSpringer, Cham., 2020.
- 615 4. **Molnar R, Madacsy T, Varga A, Nemeth M, Katona X, Gorog M, Molnar B,**
616 **Fanczal J, Rakonczay Z, Jr., Hegyi P, Pallagi P, and Maleth J.** Mouse pancreatic ductal
617 organoid culture as a relevant model to study exocrine pancreatic ion secretion. *Lab Invest*
618 100: 84-97, 2020.
- 619 5. **Sachs N, Papaspyropoulos A, Zomer-van Ommen DD, Heo I, Bottinger L, Klay**
620 **D, Weeber F, Huelsz-Prince G, Iakobachvili N, Amatngalim GD, de Ligt J, van Hoeck**
621 **A, Proost N, Viveen MC, Lyubimova A, Teeven L, Derakhshan S, Korving J, Begthel H,**
622 **Dekkers JF, Kumawat K, Ramos E, van Oosterhout MF, Offerhaus GJ, Wiener DJ,**
623 **Olimpio EP, Dijkstra KK, Smit EF, van der Linden M, Jaksani S, van de Ven M,**
624 **Jonkers J, Rios AC, Voest EE, van Moorsel CH, van der Ent CK, Cuppen E, van**
625 **Oudenaarden A, Coenjaerts FE, Meyaard L, Bont LJ, Peters PJ, Tans SJ, van Zon JS,**
626 **Boj SF, Vries RG, Beekman JM, and Clevers H.** Long-term expanding human airway
627 organoids for disease modeling. *EMBO J* 38: 2019.

- 628 6. **DeWard AD, Cramer J, and Lagasse E.** Cellular heterogeneity in the mouse
629 esophagus implicates the presence of a nonquiescent epithelial stem cell population. *Cell Rep*
630 9: 701-711, 2014.
- 631 7. **Kalabis J, Oyama K, Okawa T, Nakagawa H, Michaylira CZ, Stairs DB,**
632 **Figueiredo JL, Mahmood U, Diehl JA, Herlyn M, and Rustgi AK.** A subpopulation of
633 mouse esophageal basal cells has properties of stem cells with the capacity for self-renewal
634 and lineage specification. *J Clin Invest* 118: 3860-3869, 2008.
- 635 8. **Thomas JA, Buchsbaum RN, Zimniak A, and Racker E.** Intracellular pH
636 measurements in Ehrlich ascites tumor cells utilizing spectroscopic probes generated in situ.
637 *Biochemistry* 18: 2210-2218, 1979.
- 638 9. **Hegy P, Rakonczay Z, Jr., Gray MA, and Argent BE.** Measurement of
639 intracellular pH in pancreatic duct cells: a new method for calibrating the fluorescence data.
640 *Pancreas* 28: 427-434, 2004.
- 641 10. **Hegy P, Gray MA, and Argent BE.** Substance P inhibits bicarbonate secretion from
642 guinea pig pancreatic ducts by modulating an anion exchanger. *American journal of*
643 *physiology Cell physiology* 285: C268-276, 2003.
- 644 11. **Venglovecz V, Rakonczay Z, Jr., Ozsvari B, Takacs T, Lonovics J, Varro A, Gray**
645 **MA, Argent BE, and Hegyi P.** Effects of bile acids on pancreatic ductal bicarbonate
646 secretion in guinea pig. *Gut* 57: 1102-1112, 2008.
- 647 12. **Harnden P, and Southgate J.** Cytokeratin 14 as a marker of squamous differentiation
648 in transitional cell carcinomas. *J Clin Pathol* 50: 1032-1033, 1997.
- 649 13. **Reis-Filho JS, Simpson PT, Martins A, Preto A, Gartner F, and Schmitt FC.**
650 Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic
651 human tissue samples using TARP-4 multi-tumor tissue microarray. *Virchows Arch* 443: 122-
652 132, 2003.

- 653 14. **Fong P.** CFTR-SLC26 transporter interactions in epithelia. *Biophys Rev* 4: 107-116,
654 2012.
- 655 15. **Weintraub WH, and Machen TE.** pH regulation in hepatoma cells: roles for Na-H
656 exchange, Cl-HCO₃ exchange, and Na-HCO₃ cotransport. *The American journal of*
657 *physiology* 257: G317-327, 1989.
- 658 16. **Slepkov ER, Rainey JK, Sykes BD, and Fliegel L.** Structural and functional analysis
659 of the Na⁺/H⁺ exchanger. *Biochem J* 401: 623-633, 2007.
- 660 17. **Pallagi-Kunstar E, Farkas K, Maleth J, Rakonczay Z, Jr., Nagy F, Molnar T,**
661 **Szepes Z, Venglovecz V, Lonovics J, Razga Z, Wittmann T, and Hegyi P.** Bile acids
662 inhibit Na⁽⁺⁾/H⁽⁺⁾ exchanger and Cl⁽⁻⁾/HCO₃⁽⁻⁾ exchanger activities via cellular energy
663 breakdown and Ca⁽²⁺⁾ overload in human colonic crypts. *Pflugers Arch* 467: 1277-1290,
664 2015.
- 665 18. **Venglovecz V, Hegyi P, Rakonczay Z, Jr., Tiszlavicz L, Nardi A, Grunnet M, and**
666 **Gray MA.** Pathophysiological relevance of apical large-conductance Ca⁽²⁺⁾-activated
667 potassium channels in pancreatic duct epithelial cells. *Gut* 60: 361-369, 2011.
- 668 19. **Tobey NA, Koves G, and Orlando RC.** Human esophageal epithelial cells possess an
669 Na⁺/H⁺ exchanger for H⁺ extrusion. *Am J Gastroenterol* 93: 2075-2081, 1998.
- 670 20. **Tobey NA, Reddy SP, Keku TO, Cragoe EJ, Jr., and Orlando RC.** Studies of pH_i
671 in rabbit esophageal basal and squamous epithelial cells in culture. *Gastroenterology* 103:
672 830-839, 1992.
- 673 21. **Shallat S, Schmidt L, Reaka A, Rao D, Chang EB, Rao MC, Ramaswamy K, and**
674 **Layden TJ.** NHE-1 isoform of the Na⁺/H⁺ antiport is expressed in the rat and rabbit
675 esophagus. *Gastroenterology* 109: 1421-1428, 1995.
- 676 22. **Ariyoshi Y, Shiozaki A, Ichikawa D, Shimizu H, Kosuga T, Konishi H, Komatsu**
677 **S, Fujiwara H, Okamoto K, Kishimoto M, Marunaka Y, and Otsuji E.** Na⁺/H⁺

678 exchanger 1 has tumor suppressive activity and prognostic value in esophageal squamous cell
679 carcinoma. *Oncotarget* 8: 2209-2223, 2017.

680 23. **Guan B, Hoque A, and Xu X.** Amiloride and guggulsterone suppression of
681 esophageal cancer cell growth in vitro and in nude mouse xenografts. *Front Biol (Beijing)* 9:
682 75-81, 2014.

683 24. **Yang SC, Chen CL, Yi CH, Liu TT, and Shieh KR.** Changes in Gene Expression
684 Patterns of Circadian-Clock, Transient Receptor Potential Vanilloid-1 and Nerve Growth
685 Factor in Inflamed Human Esophagus. *Sci Rep* 5: 13602, 2015.

686 25. **Zeng C, Vanoni S, Wu D, Caldwell JM, Wheeler JC, Arora K, Noah TK,
687 Waggoner L, Besse JA, Yamani AN, Uddin J, Rochman M, Wen T, Chehade M, Collins
688 MH, Mukkada VA, Putnam PE, Naren AP, Rothenberg ME, and Hogan SP.** Solute
689 carrier family 9, subfamily A, member 3 (SLC9A3)/sodium-hydrogen exchanger member 3
690 (NHE3) dysregulation and dilated intercellular spaces in patients with eosinophilic
691 esophagitis. *J Allergy Clin Immunol* 142: 1843-1855, 2018.

692 26. **Abdulnour-Nakhoul S, Nakhoul HN, Kalliny MI, Gyftopoulos A, Rabon E,
693 Doetjes R, Brown K, and Nakhoul NL.** Ion transport mechanisms linked to bicarbonate
694 secretion in the esophageal submucosal glands. *Am J Physiol Regul Integr Comp Physiol* 301:
695 R83-96, 2011.

696 27. **Abdulnour-Nakhoul S, Nakhoul NL, Wheeler SA, Wang P, Swenson ER, and
697 Orlando RC.** HCO₃⁻ secretion in the esophageal submucosal glands. *Am J Physiol*
698 *Gastrointest Liver Physiol* 288: G736-744, 2005.

699 28. **Tobey NA, Reddy SP, Khalbuss WE, Silvers SM, Cragoe EJ, Jr., and Orlando
700 RC.** Na⁽⁺⁾-dependent and -independent Cl⁻/HCO₃⁻ exchangers in cultured rabbit esophageal
701 epithelial cells. *Gastroenterology* 104: 185-195, 1993.

- 702 29. **Wang J, Wang W, Wang H, and Tuo B.** Physiological and Pathological Functions
703 of SLC26A6. *Front Med (Lausanne)* 7: 618256, 2020.
- 704 30. **Ko SB, Zeng W, Dorwart MR, Luo X, Kim KH, Millen L, Goto H, Naruse S,**
705 **Soyombo A, Thomas PJ, and Muallem S.** Gating of CFTR by the STAS domain of SLC26
706 transporters. *Nat Cell Biol* 6: 343-350, 2004.
- 707 31. **Stewart AK, Yamamoto A, Nakakuki M, Kondo T, Alper SL, and Ishiguro H.**
708 Functional coupling of apical Cl⁻/HCO₃⁻ exchange with CFTR in stimulated HCO₃⁻ secretion
709 by guinea pig interlobular pancreatic duct. *Am J Physiol Gastrointest Liver Physiol* 296:
710 G1307-1317, 2009.
- 711 32. **Saint-Criq V, and Gray MA.** Role of CFTR in epithelial physiology. *Cell Mol Life*
712 *Sci* 74: 93-115, 2017.
- 713 33. **Kruger L, Pridgen TA, Taylor ER, Garman KS, and Blikslager AT.** Lubiprostone
714 protects esophageal mucosa from acid injury in porcine esophagus. *Am J Physiol Gastrointest*
715 *Liver Physiol* 318: G613-G623, 2020.
- 716 34. **Ao M, Venkatasubramanian J, Boonkaewwan C, Ganesan N, Syed A, Benya RV,**
717 **and Rao MC.** Lubiprostone activates Cl⁻ secretion via cAMP signaling and increases
718 membrane CFTR in the human colon carcinoma cell line, T84. *Dig Dis Sci* 56: 339-351,
719 2011.
- 720 35. **Norimatsu Y, Moran AR, and MacDonald KD.** Lubiprostone activates CFTR, but
721 not ClC-2, via the prostaglandin receptor (EP(4)). *Biochem Biophys Res Commun* 426: 374-
722 379, 2012.
- 723 36. **Gharahkhani P, Fitzgerald RC, Vaughan TL, Palles C, Gockel I, Tomlinson I,**
724 **Buas MF, May A, Gerges C, Anders M, Becker J, Kreuser N, Noder T, Venerito M,**
725 **Veits L, Schmidt T, Manner H, Schmidt C, Hess T, Bohmer AC, Izbicki JR, Holscher**
726 **AH, Lang H, Lorenz D, Schumacher B, Hackelsberger A, Mayershofer R, Pech O,**

727 **Vashist Y, Ott K, Vieth M, Weismuller J, Nothen MM, Barrett's, Esophageal**
728 **Adenocarcinoma C, Esophageal Adenocarcinoma GenEtics C, Wellcome Trust Case**
729 **Control C, Attwood S, Barr H, Chegwiddden L, de Caestecker J, Harrison R, Love SB,**
730 **MacDonald D, Moayyedi P, Prenen H, Watson RGP, Iyer PG, Anderson LA, Bernstein**
731 **L, Chow WH, Hardie LJ, Lagergren J, Liu G, Risch HA, Wu AH, Ye W, Bird NC,**
732 **Shaheen NJ, Gammon MD, Corley DA, Caldas C, Moebus S, Knapp M, Peters WHM,**
733 **Neuhaus H, Rosch T, Ell C, MacGregor S, Pharoah P, Whiteman DC, Jankowski J, and**
734 **Schumacher J.** Genome-wide association studies in oesophageal adenocarcinoma and
735 Barrett's oesophagus: a large-scale meta-analysis. *Lancet Oncol* 17: 1363-1373, 2016.

736 37. **Hassall E, Israel DM, Davidson AG, and Wong LT.** Barrett's esophagus in children
737 with cystic fibrosis: not a coincidental association. *Am J Gastroenterol* 88: 1934-1938, 1993.

738 38. **Holt EW, Yimam KK, and Liberman MS.** Esophageal adenocarcinoma in a 40-
739 year-old man with cystic fibrosis: coincidence or not? *Ochsner J* 13: 252-255, 2013.

740 39. **Li W, Wang C, Peng X, Zhang H, Huang H, and Liu H.** CFTR inhibits the invasion
741 and growth of esophageal cancer cells by inhibiting the expression of NF-kappaB. *Cell Biol*
742 *Int* 42: 1680-1687, 2018.

743 40. **Matsumoto Y, Shiozaki A, Kosuga T, Kudou M, Shimizu H, Arita T, Konishi H,**
744 **Komatsu S, Kubota T, Fujiwara H, Okamoto K, Kishimoto M, Konishi E, and Otsuji E.**
745 Expression and Role of CFTR in Human Esophageal Squamous Cell Carcinoma. *Ann Surg*
746 *Oncol* 2021.

747 41. **Vanoni S, Zeng C, Marella S, Uddin J, Wu D, Arora K, Ptaschinski C, Que J,**
748 **Noah T, Waggoner L, Barski A, Kartashov A, Rochman M, Wen T, Martin L, Spence J,**
749 **Collins M, Mukkada V, Putnam P, Naren A, Chehade M, Rothenberg ME, and Hogan**
750 **SP.** Identification of anoctamin 1 (ANO1) as a key driver of esophageal epithelial
751 proliferation in eosinophilic esophagitis. *J Allergy Clin Immunol* 145: 239-254 e232, 2020.

Figure 1






Figure 2







Figure 3

A



B



C




Figure 4




Figure 5




Figure 6







Figure 7

A



B




Figure 8




Figure 9





Figure 10



| | Standard HEPES | Standard HCO ₃ ⁻ | NH ₄ Cl HEPES | High-K ⁺ HEPES | NH ₄ Cl HCO ₃ ⁻ | Na ⁺ -free HEPES | Na ⁺ -free HCO ₃ ⁻ | Cl ⁻ -free HEPES | Cl ⁻ -free HCO ₃ ⁻ |
|---------------------------------------|-------------------|---|-----------------------------|------------------------------|---|--------------------------------|--|--------------------------------|--|
| NaCl | 140 | 115 | 110 | 5 | 95 | | | | |
| KCl | 5 | 5 | 5 | 130 | 5 | 5 | 5 | | |
| MgCl ₂ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | |
| CaCl ₂ | 1 | 1 | 1 | 1 | 1 | 1 | 1 | | |
| HEPES acid | 10 | | 10 | | | 10 | | 10 | |
| Glucose | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 |
| NaHCO ₃ | | 25 | | | 25 | | | | 25 |
| NH ₄ Cl | | | 20 | | 20 | | | | |
| Na-HEPES | | | | 10 | | | | | |
| NMDG-Cl | | | | | | 140 | 115 | | |
| Na-gluconate | | | | | | | | 140 | 115 |
| Mg-gluconate | | | | | | | | 1 | 1 |
| Ca-gluconate | | | | | | | | 6 | 6 |
| K ₂ -sulfate | | | | | | | | 2.5 | 2.5 |
| Choline HCO ₃ ⁻ | | | | | | | 25 | | |
| Atropine | | | | | | | 0.01 | | |

Table 1

| Primary antibodies | Company | Cat. No. | Dilution |
|---------------------------|-----------------------------|-----------------|-----------------|
| Slc9a1 | Alomone | ANX-010 | 1:100 |
| Slc9a2 | Alomone | ANX-002 | 1:100 |
| Slc26a3 | Invitrogen | PA5-68530 | 1:600 |
| Slc26a6 | Santa Cruz Biotechnology | sc-515230 | 1:200 |
| Slc4a4 | Abcam | ab187511 | 1:100 |
| CFTR | Alomone | ACL-006 | 1:200 |
| ANO1 | Alomone | ACL-011 | 1:200 |

Table 2

| Gene | Reverse primer | Forward primer | Product size (bp) |
|----------------|-----------------------|-----------------------|--------------------------|
| Slc9a1 | TGGCTCTACTGTCCTTTGGG | GAGGAGGAAGATGAGGACGG | 194 |
| Slc9a2 | GAAATCAGGCTGCCGAAGAG | CTACTTCATGCCAACTCGCC | 183 |
| Slc26a3 | ACCCTTTGAGATGGTCCAGG | TTCCTTCCCCTAGCCACTG | 161 |
| Slc26a6 | AGCTCCTGGTTACTGTCCAC | TCATTGGGGCCACTGGTATT | 235 |
| Slc4a4 | CAGCCACATACCAGGGAAGA | CGGCTTTGCTAGTCACCATC | 171 |
| CFTR | TCTGCATGGGTTCTGGGAAT | GAGCAATGTCTGGCAGTACG | 249 |
| ANO1 | GGGGCTGTGGTTGTTACAAG | ATCCCCAAAGACATCAGCCA | 150 |

Table 3